Cargando…
A novel in silico scaffold-hopping method for drug repositioning in rare and intractable diseases
In the field of rare and intractable diseases, new drug development is difficult and drug repositioning (DR) is a key method to improve this situation. In this study, we present a new method for finding DR candidates utilizing virtual screening, which integrates amino acid interaction mapping into s...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632405/ https://www.ncbi.nlm.nih.gov/pubmed/37938624 http://dx.doi.org/10.1038/s41598-023-46648-1 |
_version_ | 1785132569085345792 |
---|---|
author | Tanabe, Mao Sakate, Ryuichi Nakabayashi, Jun Tsumura, Kyosuke Ohira, Shino Iwato, Kaoru Kimura, Tomonori |
author_facet | Tanabe, Mao Sakate, Ryuichi Nakabayashi, Jun Tsumura, Kyosuke Ohira, Shino Iwato, Kaoru Kimura, Tomonori |
author_sort | Tanabe, Mao |
collection | PubMed |
description | In the field of rare and intractable diseases, new drug development is difficult and drug repositioning (DR) is a key method to improve this situation. In this study, we present a new method for finding DR candidates utilizing virtual screening, which integrates amino acid interaction mapping into scaffold-hopping (AI-AAM). At first, we used a spleen associated tyrosine kinase inhibitor as a reference to evaluate the technique, and succeeded in scaffold-hopping maintaining the pharmacological activity. Then we applied this method to five drugs and obtained 144 compounds with diverse structures. Among these, 31 compounds were known to target the same proteins as their reference compounds and 113 compounds were known to target different proteins. We found that AI-AAM dominantly selected functionally similar compounds; thus, these selected compounds may represent improved alternatives to their reference compounds. Moreover, the latter compounds were presumed to bind to the targets of their references as well. This new “compound-target” information provided DR candidates that could be utilized for future drug development. |
format | Online Article Text |
id | pubmed-10632405 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-106324052023-11-10 A novel in silico scaffold-hopping method for drug repositioning in rare and intractable diseases Tanabe, Mao Sakate, Ryuichi Nakabayashi, Jun Tsumura, Kyosuke Ohira, Shino Iwato, Kaoru Kimura, Tomonori Sci Rep Article In the field of rare and intractable diseases, new drug development is difficult and drug repositioning (DR) is a key method to improve this situation. In this study, we present a new method for finding DR candidates utilizing virtual screening, which integrates amino acid interaction mapping into scaffold-hopping (AI-AAM). At first, we used a spleen associated tyrosine kinase inhibitor as a reference to evaluate the technique, and succeeded in scaffold-hopping maintaining the pharmacological activity. Then we applied this method to five drugs and obtained 144 compounds with diverse structures. Among these, 31 compounds were known to target the same proteins as their reference compounds and 113 compounds were known to target different proteins. We found that AI-AAM dominantly selected functionally similar compounds; thus, these selected compounds may represent improved alternatives to their reference compounds. Moreover, the latter compounds were presumed to bind to the targets of their references as well. This new “compound-target” information provided DR candidates that could be utilized for future drug development. Nature Publishing Group UK 2023-11-08 /pmc/articles/PMC10632405/ /pubmed/37938624 http://dx.doi.org/10.1038/s41598-023-46648-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Tanabe, Mao Sakate, Ryuichi Nakabayashi, Jun Tsumura, Kyosuke Ohira, Shino Iwato, Kaoru Kimura, Tomonori A novel in silico scaffold-hopping method for drug repositioning in rare and intractable diseases |
title | A novel in silico scaffold-hopping method for drug repositioning in rare and intractable diseases |
title_full | A novel in silico scaffold-hopping method for drug repositioning in rare and intractable diseases |
title_fullStr | A novel in silico scaffold-hopping method for drug repositioning in rare and intractable diseases |
title_full_unstemmed | A novel in silico scaffold-hopping method for drug repositioning in rare and intractable diseases |
title_short | A novel in silico scaffold-hopping method for drug repositioning in rare and intractable diseases |
title_sort | novel in silico scaffold-hopping method for drug repositioning in rare and intractable diseases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632405/ https://www.ncbi.nlm.nih.gov/pubmed/37938624 http://dx.doi.org/10.1038/s41598-023-46648-1 |
work_keys_str_mv | AT tanabemao anovelinsilicoscaffoldhoppingmethodfordrugrepositioninginrareandintractablediseases AT sakateryuichi anovelinsilicoscaffoldhoppingmethodfordrugrepositioninginrareandintractablediseases AT nakabayashijun anovelinsilicoscaffoldhoppingmethodfordrugrepositioninginrareandintractablediseases AT tsumurakyosuke anovelinsilicoscaffoldhoppingmethodfordrugrepositioninginrareandintractablediseases AT ohirashino anovelinsilicoscaffoldhoppingmethodfordrugrepositioninginrareandintractablediseases AT iwatokaoru anovelinsilicoscaffoldhoppingmethodfordrugrepositioninginrareandintractablediseases AT kimuratomonori anovelinsilicoscaffoldhoppingmethodfordrugrepositioninginrareandintractablediseases AT tanabemao novelinsilicoscaffoldhoppingmethodfordrugrepositioninginrareandintractablediseases AT sakateryuichi novelinsilicoscaffoldhoppingmethodfordrugrepositioninginrareandintractablediseases AT nakabayashijun novelinsilicoscaffoldhoppingmethodfordrugrepositioninginrareandintractablediseases AT tsumurakyosuke novelinsilicoscaffoldhoppingmethodfordrugrepositioninginrareandintractablediseases AT ohirashino novelinsilicoscaffoldhoppingmethodfordrugrepositioninginrareandintractablediseases AT iwatokaoru novelinsilicoscaffoldhoppingmethodfordrugrepositioninginrareandintractablediseases AT kimuratomonori novelinsilicoscaffoldhoppingmethodfordrugrepositioninginrareandintractablediseases |